The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Aducanumab for Alzheimer’s disease?
Abstract
Patients and families need hope, not false hope
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an IgG1 monoclonal antibody, aducanumab binds to extracellular Aβ plaques to eliminate them.422,423”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [423]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Alexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA · doi:10.1001/jama.2021.3854 · Cited by 240
France removes state funding for dementia drugs
Walsh, S., King, E., & Brayne, C. (2019) · BMJ · doi:10.1136/bmj.l6930 · Cited by 25
Self-citation
Research works printed but not linked: 4
- 10.1136/bmj.n1503 · DOI
- 10.1136/bmj.n156 · DOI · Paper page
- 10.1002/alz.12379 · DOI
- 10.1038/d41586-021-01546-2 · DOI
Cited by
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
Solving neurodegeneration: common mechanisms and strategies for new treatments
Wareham, L. K., Liddelow, S. A., Temple, S., Benowitz, L. I., Di Polo, A., Wellington, C., Goldberg, J. L., He, Z., Duan, X., Bu, G., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00524-0 · Cited by 324
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
“Finally, there was controversy over the FDA prescribing label for aducanumab because it was initially approved for anyone with AD, despite the trials only enrolled MCI and mild AD patients.(13) Only after a month, the FDA narrowed the indication to MCI and mild AD.”
BackgroundLecanemab for Alzheimer’s disease
Walsh, S., Merrick, R., Richard, E., Nurock, S., & Brayne, C. (2022) · BMJ · doi:10.1136/bmj.o3010 · Cited by 76
Self-citationGenomics and Functional Genomics of Alzheimer's Disease
Kamboh, M. I. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01152-0 · Cited by 73
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Talar, K., Vetrovsky, T., van Haren, M., Négyesi, J., Granacher, U., Váczi, M., Martín-Arévalo, E., Del Olmo, M. F., Kałamacka, E., & Hortobágyi, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101738 · Cited by 59
Current landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Ischemia as a common trigger for Alzheimer’s disease
Elman-Shina, K., & Efrati, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1012779 · Cited by 48
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42
Walsh, S., Brain, J., Mukadam, N., Anderson, R., Greene, L., Govia, I., Kuhn, I., Anstey, K. J., Knapp, M., Stephan, B. C. M., et al. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.09.002 · Cited by 33
Self-citationp53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Yeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
New biologicals and biomaterials in the therapy of Alzheimer's disease
Prajapati, V., Shinde, S., Shrivastav, P., & Prajapati, B. G. (2024) · Alzheimer's Disease and Advanced Drug Delivery Strategies · doi:10.1016/b978-0-443-13205-6.00016-9 · Cited by 7
Metadata
- Authors
- Walsh, S., Merrick, R., Milne, R., & Brayne, C.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-07-05
- Pages
- n1682
- ISSN
- 1756-1833
- Cited by
- 159
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.